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Background: Clopidogrel has been the only available antiplatelet drug used along with
aspirin in patients of ACS. In recent years 2 new antiplatelet drugs (Prasugrel and Tica-
grelor) have become available. Prasugrel in the dose of 10 mg OD has been found to be more
efficacious but with increased risk of major bleeding. For this reason it has not gained
widespread usage in ACS patients undergoing PCI. There are no systematic data on the use
of Prasugrel in Indian population.
Method: This is a prospective, multicentric, hospital registry of 1000 patients with ACS
undergoing PCI who were administered Prasugrel. The primary safety endpoint of this
study was major and minor bleeding while the efficacy endpoint is the composite of CV
death, nonfatal MI, nonfatal stroke up to 30 days after PCI. Patients with high bleeding risk
were excluded.
Results: Most patients (91%) received loading dose of Prasugrel along with the maintenance
dose getting according to the defined protocol. Patients were followed up to 30 days postInstitute, Okhla Road, New Delhi 110025 India. Tel.: þ91 9811150518, þ91 11 47135000; fax:
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i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 5 9 8e6 0 1 599procedure. Primary efficacy end point was reached in 3 patients only with two of them
dying due to possible stent thrombosis and the third requiring revascularization of the
target vessel for stent thrombosis. One major and 19 minor bleeding complications were
recorded, with access site bleeding in 0.7% & non-access site bleeding in 1.2% of the
subjects.
Conclusion: Prasugrel was found to be effective & not associated with a high incidence of
bleeding in the high risk ACS patients when those at a high bleeding risk were excluded.
Copyright © 2014, Cardiological Society of India. All rights reserved.1. Background
Dual antiplatelet therapy with aspirin and clopidogrel has
been established to be efficacious in the treatment of acute
coronary syndrome with PCI. However many patients
continue to have recurrent atherothrombotic events on this
therapy despite these positive effects. More over delayed
onset of action and modest antiplatelet effect with significant
interpatient variability has led to the development of newer
antiplatelet drugs.
Prasugrel, a prodrug, needs to be converted to its active
metabolite before binding to the platelet P2Y12 receptor to
have its antiplatelet effect. Its efficacy has been well estab-
lished in both phase 2 and phase 3 trials testing Prasugrel as
compared to standard dose clopidogrel in patients undergoing
PCI for ACS. Results revealed positive trends towards reduced
ischaemic events i.e. significantly less nonfatal MI & signifi-
cantly lower rate of stent thrombosis in the follow up period.
These benefits were limited by more complications including
higher rate of both life-threatening & fatal bleeding as
compared to clopidogrel. These side effects were however
found to be more in specified high risk subgroups like elderly
age group (>75 yrs), previous stroke/TIA and those weighing
less than 60 kg, with no net benefit.1 Hence the drug has not
gained widespread usage especially in our country because of
the fear of bleeding. TRITON TIMI 38 had no subjects included
from South Asian countries as also lack of systematic Indian
data on the subject led us to plan this multicentric registry in
order to find out the incidence of bleeding complications with
use of Prasugrel in conjunction with aspirin, as well as to
establish its efficacy in our kind of population.2. Methods
This is a prospective investigator initiated multicentric hos-
pital registry.
2.1. Study population
1000 patients, presenting with ACS and scheduled to undergo
PCI & given Prasugrel along with aspirin as antiplatelet agents
were included in the study. ACS included both unstable
angina & NSTEMI diagnosed as per standard definitions as
well as STEMI i.e. primary PCI as also those undergoing
delayed PCI following initial medical management.2.2. Exclusions
Patients with CVA/TIA (diagnosed significant intracranial pa-
thology), those >75 yrs of age and those weighing <60 kg were
excluded from the study as well as the ones with increased
risk of bleeding, anaemia or thrombocytopenia.2.3. Study protocol
Those included in the study received loading dose of Prasugrel
(60 mg) following delineation of the coronary status and
maintained by 10 mg once daily. Patients preloaded with
clopidogrel and subsequently switched over to Prasugrel
maintenance dose were also included in the registry. The
protocol for such patients was that if preloading was done
with clopidogrel 600 mg within previous one week then it was
followed up with only maintenance dose of Prasugrel 10 mg
once daily. Patients on maintenance dose of clopidogrel for
over a week were reloaded with Prasugrel with subsequent
maintenance dose of Prasugrel (SWAP study).2 Choice of the
number of vessels treated and use of adjunctive medication
during PCI was left to the treating physician. After enrolment
patients were maintained on standard medication and were
followed up physically at screening, at baseline & loading
dose, at 24 h and at 30 days post procedure with a telephonic
review at 15 days in between.2.4. End points
Primary safety end point was TIMI major bleeding not related
to CABG, non CABG related life-threatening & TIMI major and
minor bleeding.3
Efficacy was studied by a composite of cardiovascular
death, nonfatal MI and nonfatal stroke up to 30 days post
procedure.
Stent thrombosis was defined as definite/probable stent
thrombosis according to ARC criteria.
The study had approval of the local Ethics committees and
written informed consent was taken from all the participants.3. Results
A total of 1000 patients undergoing PCI for Acute coronary
syndrome & treated with prasugrel were included in the
study. The mean age of the patients was 55.99 yrs. Average
Table 2 e Adverse events (n).
Death (possible stent thrombosis) 2
Target vessel revascularization 1
Different vessel intervention 2
Rehospitalisation
Cardiac cause 0
Non cardiac cause 2
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weremales. Hypertensionwas the commonest associated risk
factor, about 50% and 38.9% were diabetics. Tobacco use was
seen in 25.7% of the study population. The indications for PCI
included 49.5% unstable angina, 19.4% NSTEMI and 31.1%
STEMI (Table 1). Most of the patients were given Prasugrel
subsequent to the delineation of their coronary anatomy
following an angiogram.
Majority of the patients (90.9%) received loading dose
(60 mg) either pre-procedure or during procedure and were
followed up with 10 mg once daily whereas the rest 9.1% (who
had been preloaded with clopidogrel) were given only the
maintenance dose i.e. 10 mg once daily. Almost all the pa-
tients got a DES placed during the procedure with a few un-
dergoing PCI with DEB for specified indications.
A total of 26 adverse events were noticed during the study
period. Primary efficacy end point was reached in 3 patients
with two of them died due to possible stent thrombosis and
the third required revascularization of the target vessel for
stent thrombosis. A different vessel intervention (although
not a study end point) was required in 2 patients as also two
other patients required hospitalization, however for non car-
diac issues (Table 2). Safety end points were noticed in 20 of
the subjects with one patient while undergoing delayed an-
gioplasty following an STEMI, developed hemorrhagic peri-
cardial effusion following 2 days post PCI and required
surgical drainage for relief from the resulting tamponade. The
other 19 patients experienced minor bleeds in the form of
access site i.e. groin haematomas (0.7%), and non access site
(1.2%) i.e. epistaxis, gum bleeding and bleeding from hae-
morrhoids (Table 3).4. Discussion
Antiplatelet therapy is the corner stone in the success of PCI.
Various drugs have been in vogue for the purpose with rising
interest in the development of newer agents with improved
efficacy & reduced side effects profile. Prasugrel & Ticagrelor
are two such agents which have been extensively studied &
and found to be more efficacious in most of the situations
barring a few conditions (with high bleeding risk). TRITONTable 1 e Baseline characteristics of the patients
(n ¼ 1000).
Mean Age (yrs) 55.99
ACS
NSTEMI n (%) 194 (19.4)
Unstable angina n (%) 495 (49.5)
STEMI n (%) 311 (31.1)
Risk factors
Hypertension n (%) 502 (50.2)
Diabetes Mellitus n (%) 389 (38.9)
Tobacco use n (%) 257 (25.7)
Previous history
MI n (%) 100 (10)
CABG n (%) 23 (2.3)
Anti thrombin used
Heparin n (%) 545 (54.5)
Heparin þ GPI n (%) 245 (24.5)
Bivalirudin n (%) 210 (21)TIMI 381 was one such trial involving over 13000 moderate -
high risk Acute Coronary Syndrome patients, where its
significantly higher efficacy in terms of composite of death,
non fatal MI/urgent TVR and stent thrombosis was estab-
lished beyond doubt. The effect was noticed to be more pro-
nounced in STEMI patients.
Mean age of patients included in our study was 55.99 yrs. It
is significantly younger than those included in the major trial
testing Prasugrel i.e. 61 yrs. in TRITON TIMI 38. Whereas
number of diabetics included were 38.9% in our study vs. 23%
in TRITON TIMI 38. STEMIs constituted 31.1% of our study
population as compared to 26% in TRITON TIMI 38. All these
findings re-emphasize that our population is more prone to
have diabetes and coronary artery disease at a relatively
younger age, as well as STEMI may be a more common pre-
sentation in our part of the world.
With regards to efficacy of the study drug, we observed
0.3% primary composite end point at 30 days post procedure
whereas primary efficacy end point was seen in 6.5% of pa-
tients receiving Prasugrel at 30 days & 9.9% of patients at 15
months with 7.4% having MI, 2.5% requiring urgent TVR &
1.1% having stent thrombosis in TRITON TIMI 38 (Table 4).
This difference could possibly be due to relatively younger &
probably more stable population included in our study as well
as especially with exclusion of the high risk elderly population
as indicated by TRITON TIMI 38 should have affected the
outcome to such a degree.
As with any other antiplatelet drug, bleeding was the
commonest side effect noticed with Prasugrel. We found
major bleeding in only one patient (0.1%) and minor bleeding
in another 1.9% of the patients at 30 days post procedure.
TRITON TIMI 38 revealed that at 30 days bleeding complica-
tions occurred similarly in both Prasugrel (1.03%) and Clopi-
dogrel (0.87%) arms (Table 5). However by the end of the study
(at 15months) the bleeding rates significantly increased to the
tune of 2.4%with Prasugrel as compared to 1.8% patients with
clopidogrel including both life-threatening bleeding (non
fatal/fatal bleeding). Similar rates of bleeding have earlier
been reported with clopidogrel in CURE4 (clopidogrel vs. pla-
cebo) major bleed was seen in 3.7% vs. 2.7% placebo. CLARITY
TIMI 285 showed in STEMI patients that Clopidogrel & Placebo
groups had similar number of bleeding complications.
COMMIT6 (STEMI) study again revealed no significant differ-
ences in bleeding episodes. CREDO7 e an observational study
similarly showed low incidence of bleeding. These differences
in the efficacy & safety parameters as compared to previous
large scale studies could possibly be due to exclusion ofTable 3 e Bleeding rates (n ¼ 1000).
Access site n (%) 7 (0.7)
Non access site n (%) 12 (1.2)
Table 4 e Efficacy (primary composite end point) (%).
Our registry (30 days) TRITON TIMI 381 (15 months) PCI-CURE8 (8 months) PLATO9 (12 months)
Prasugrel Prasugrel Clopidogrel Placebo Clopidogrel Ticagrelor Clopidogrel
0.3 9.9 12.1 6.4 4.5 9.8 11.1
Table 5 e Comparison of major bleeding rates in important trials (%).
Time Our registry TRITON TIMI 381 PCI-CURE8 PLATO9
Prasugrel Prasugrel Clopidogrel Placebo Clopidogrel Ticagrelor Clopidogrel
30 days 0.1 1.03 0.87 1.4 1.6 NA NA
End of study NA 2.4 1.8 2.5 2.7 7.9 7.7
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weight < 60 kg & previous h/o bleed (intra cerebral). Barring
these situations Prasugrel was found to be as efficacious as
reported earlier & was also found to be relatively safe & may
not be as risky as with inclusion of all unselective cases.5. Conclusions
In the background of acute coronary syndrome, patients
scheduled to undergo PCI, when given Prasugrel, was associ-
ated with significantly reduced incidence of primary events as
shown in earlier trials. Non inclusion of the patients at high
risk of bleeding as seen in our study leads to very low bleeding
events and favourable outcomes in most. Prasugrel may thus
be amore efficacious& less complicating drug in high risk ACS
patients.6. Limitations
It was an exploratory study where bleeding rates were
observed to be comparatively quite low and thus making it
difficult for any kind of subset analysis. Moreover follow up
was undertaken up to 30 days post procedure which could
have possibly excluded the bleeding episodes which might
occur on prolonged maintenance dosages.Conflicts of interest
All authors have none to declare.
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